Within the space of just a few years, several new retinal treatments have been approved for age-related macular degeneration (AMD) and diabetic retinopathy/diabetic macular edema (DR/DME), promising increased durability and better patient outcomes. These conditions can significantly impact vision and quality of life for patients. Retinal specialists are using a combination of traditional therapies, such as anti-vascular endothelial growth factor (anti-VEGF) injections, as well as emerging therapies, like sustained-release drug delivery systems, and other innovative approaches. The involvement of payers in the management of retinal diseases is essential to ensure that treatments are accessible to patients who need them. It is an exciting time in the field of retinal medicine, with advancements in treatment options and the opportunity for collaboration between retinal specialists and payers to improve the quality of patient care while also managing costs.
- Provider:Medical Education Resources
- Activity Link: https://managedcareeye.com
- Start Date: 2024-08-15 05:00:00
- End Date: 2024-08-15 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.25 hours
Nursing: 1.25 hours
Pharmacy: 1.25 hours - Commercial Support: Source: Regeneron Pharmaceuticals, Inc. - Amount: 75000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all